Sign In
Buy BLFS
$27.25
-0.240 (-0.87%)
At Close: Jun 03, 2026
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results - Earnings Call Transcript
03:15am, Tuesday, 01'st Mar 2022 Seeking Alpha
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
11:15pm, Monday, 28'th Feb 2022 Zacks Investment Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results - Earnings Call Transcript
10:15pm, Monday, 28'th Feb 2022
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results - Earnings Call Transcript
BioLife Solutions GAAP EPS of -$0.37 misses by $0.20, revenue of $37.3M beats by $0.87M
09:19pm, Monday, 28'th Feb 2022 Seeking Alpha
BioLife Solutions press release (BLFS): Q4 GAAP EPS of -$0.37 misses by $0.20.Revenue of $37.3M (+153.7% Y/Y) beats by $0.87M.Initial guidance for 2022 total revenue at $159.5…
BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results | MarketScreener
09:04pm, Monday, 28'th Feb 2022 MarketScreener
BOTHELL, Wash., Feb. 28, 2022 /PRNewswire/ -- BioLife Solutions, Inc. , a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies… | February 28, 2022
BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results
09:03pm, Monday, 28'th Feb 2022 PR Newswire
BOTHELL, Wash., Feb. 28, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today…
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
07:53pm, Monday, 28'th Feb 2022
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022
08:03am, Monday, 21'st Feb 2022
BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an
PETQ or BLFS: Which Is the Better Value Stock Right Now?
04:40pm, Friday, 11'th Feb 2022 Zacks Investment Research
PETQ vs. BLFS: Which Stock Is the Better Value Option?
PETQ or BLFS: Which Is the Better Value Stock Right Now?
01:05pm, Friday, 11'th Feb 2022
PETQ vs. BLFS: Which Stock Is the Better Value Option?
Best Biotech Stocks to Invest in Now
12:59pm, Friday, 28'th Jan 2022
Try your hand at morphing science and business for a great investment opportunity in biotech.
BioLife: Poised For Growth
03:14pm, Wednesday, 22'nd Dec 2021
BioLife Solution is enjoying robust growth years over years.
Stephens Investment Management Group LLC Has $9.27 Million Stake in BioLife Solutions, Inc. (NASDAQ:BLFS)
01:24pm, Thursday, 16'th Dec 2021 Transcript Daily
Stephens Investment Management Group LLC lifted its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 72.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 219,059 shares of the medical equipment providers stock after acquiring an additional 92,132 shares during the period. Stephens Investment Management Group LLCs holdings in BioLife Solutions were []
BioLife Solutions (BLFS) Investor Presentation - Slideshow
09:31pm, Thursday, 09'th Dec 2021 Seeking Alpha
Perkins Capital Management Inc. Sells 1,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)
03:50pm, Thursday, 09'th Dec 2021 Transcript Daily
Perkins Capital Management Inc. decreased its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 4.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,000 shares of the medical equipment providers stock after selling 1,000 shares during the quarter. Perkins Capital Management Inc. owned []
